116,623 Shares in AnaptysBio, Inc. $ANAB Acquired by Exome Asset Management LLC

Key Points

• Exome Asset Management LLC purchased 116,623 shares of AnaptysBio, Inc. valued at approximately $2,168,000, making it the fund's 25th largest holding.
• Analysts have given AnaptysBio a consensus rating of "Moderate Buy" with an average target price of $46.13, with several brokerages recently increasing their target prices.
• Insider activity includes Director Hollings Renton selling 20,925 shares for a total of approximately $493,202, resulting in an 80.82% decrease in their position.

Exome Asset Management LLC purchased a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 116,623 shares of the biotechnology company's stock, valued at approximately $2,168,000. AnaptysBio makes up 1.8% of Exome Asset Management LLC's portfolio, making the stock its 25th largest position. Exome Asset Management LLC owned approximately 0.40% of AnaptysBio as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ANAB. First Light Asset Management LLC grew its position in AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Sanofi purchased a new position in AnaptysBio in the fourth quarter worth about $10,882,000. Soleus Capital Management L.P. purchased a new position in AnaptysBio in the fourth quarter worth about $5,481,000. Caption Management LLC grew its position in AnaptysBio by 106.3% in the first quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company's stock worth $435,000 after acquiring an additional 394,634 shares in the last quarter. Finally, 683 Capital Management LLC purchased a new position in AnaptysBio in the first quarter worth about $3,637,000.

AnaptysBio Trading Up 0.9%

Shares of NASDAQ ANAB traded up $0.20 during trading hours on Friday, reaching $23.40. The stock had a trading volume of 472,652 shares, compared to its average volume of 401,521. The firm has a market cap of $655.20 million, a price-to-earnings ratio of -5.22 and a beta of -0.19. The business's fifty day moving average price is $23.07 and its two-hundred day moving average price is $21.13. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $40.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million during the quarter, compared to analyst estimates of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. Equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANAB has been the subject of several recent research reports. Wedbush lifted their price target on AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and boosted their target price for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. UBS Group restated a "neutral" rating and set a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Finally, Guggenheim restated a "buy" rating and set a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of "Moderate Buy" and a consensus target price of $46.13.

Insider Activity

In related news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the completion of the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 33.50% of the company's stock.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.